TP53 and prostate cancer: Significantly, a bioinformatics study revealed a stepwise increase of TP53 mutations toward prostate cancer aggressiveness, showing the lowest expression in benign prostatic hyperplasia (19.0%), followed by primary prostate cancer (26.2%), and finally, metastatic castration-resistant disease (53.3%) (Schlechte et al., 1998; Network, 2015; Robinson et al., 2015).